Intercept’s NASH Hopes: A Case Study For Implications Of US Pricing Bill
• By Michael McCaughan
The drug pricing legislation under consideration in Congress could change the development strategy for products targeting liver disease and every other condition. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
